Eli Lilly Reports Stellar Q2 Performance

Eli Lilly and Company has announced a remarkable 38% annual increase in its second-quarter revenue for the fiscal year 2025, reaching an impressive $15.56 billion. The company's net income witnessed a staggering 91% surge to $5.66 billion, with earnings per share (EPS) climbing by 92% to $6.29. In light of these results, Eli Lilly has optimistically adjusted its full-year revenue guidance to between $60 billion and $62 billion.

Advancements in Pipeline Highlighted

CEO David A. Ricks shared insights into the company's progress, stating, "Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health." Notably, Mounjaro demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease, and orforglipron showed strong data in obesity treatment.

Market Reaction

Despite the positive financial results, Lilly's futures experienced a 12.29% drop, partly due to concerns over the weight-loss medicine orforglipron study's outcomes.